$JNJ has released its Q4 2024 earnings report, showcasing a solid operational growth of 6.7% in worldwide sales, reaching $22.5B, driven by robust performance in Innovative Medicine and MedTech sectors. Key highlights include a notable 23.5% growth in DARZALEX sales. However, risks loom as Stelar’s growth is hindered by biosimilar competition. Future outlook suggests a steady 3% operational sales growth in 2025 with an anticipated 9% EPS increase.